Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F19%3A00123168" target="_blank" >RIV/00216224:14110/19:00123168 - isvavai.cz</a>

Alternative codes found

RIV/00209805:_____/19:00078214

Result on the web

<a href="https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5909-5" target="_blank" >https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5909-5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s12885-019-5909-5" target="_blank" >10.1186/s12885-019-5909-5</a>

Result language

angličtina

Original language name

Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness

Original language description

BackgroundIn a prospective study with long-term follow-up, we analyzed circulating T cell subsets in patients with metastatic colorectal cancer (mCRC) in the context of primary tumor sidedness, KRAS status, and clinical outcome. Our primary goal was to investigate whether baseline levels of circulating T cell subsets serve as a potential biomarker of clinical outcome of mCRC patients treated with an anti-VEGF-based regimen.MethodsThe study group consisted of 36 patients with colorectal adenocarcinoma who started first-line chemotherapy with bevacizumab for metastatic disease. We quantified T cell subsets including Tregs and CD8(+) T cells in the peripheral blood prior to therapy initiation. Clinical outcome was evaluated as progression-free survival (PFS), overall survival (OS), and objective response rate (ORR).Results1) mCRC patients with KRAS wt tumors had higher proportions of circulating CD8(+) cytotoxic T cells among all T cells but also higher measures of T regulatory (Treg) cells such as absolute count and a higher proportion of Tregs in the CD4(+) subset. 2) A low proportion of circulating Tregs among CD4(+) cells, and a high CD8:Treg ratio at initiation of VEGF-targeting therapy, were associated with favorable clinical outcome. 3) In a subset of patients with primarily right-sided mCRC, superior PFS and OS were observed when the CD8:Treg ratio was high.ConclusionsThe baseline level of circulating immune cells predicts clinical outcome of 1st-line treatment with the anti-VEGF angio/immunomodulatory agent bevacizumab. Circulating immune biomarkers, namely the CD8:Treg ratio, identified patients in the right-sided mCRC subgroup with favorable outcome following treatment with 1st-line anti-VEGF treatment.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30230 - Other clinical medicine subjects

Project

<a href="/en/project/LM2015090" target="_blank" >LM2015090: Czech National Node to the European Clinical Research Infrastructure Network</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

BMC Cancer

ISSN

1471-2407

e-ISSN

—

Volume of the periodical

19

Issue of the periodical within the volume

687

Country of publishing house

GB - UNITED KINGDOM

Number of pages

9

Pages from-to

1-9

UT code for WoS article

000475706700010

EID of the result in the Scopus database

—